Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | CPT2 | P23786 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8789070 | 0.82 | TDP1 (0.48) | TDP1FFAR1CPT2TSHRALDH1A1 | |
| SCHEMBL8085003 | 0.82 | TDP1 (0.48) | TDP1FFAR1CPT2TSHRALDH1A1 | |
| SCHEMBL1078361 | 0.80 | ALDH1A1 (0.36) | TDP1TSHRALDH1A1FDPSHSD17B10 | |
| SCHEMBL1454489 | 0.79 | — | — | |
| SCHEMBL1132535 | 0.78 | HMGCR (0.44) | HMGCRCHRM1TBXA2RADRA1ATDP1 | |
| SCHEMBL2706813 | 0.78 | ALDH1A1 (0.45) | HMGCRCHRM1TBXA2RADRA1ATDP1 | |
| SCHEMBL2652438 | 0.77 | ALDH1A1 (0.36) | HMGCRCHRM1TBXA2RADRA1ATDP1 | |
| SCHEMBL9620491 | 0.77 | FFAR1 (0.52) | HMGCRCHRM1TBXA2RADRA1ATDP1 | |
| Methyl Alcohol SCHEMBL3697711 | 0.77 | HMGCR (0.42) | HMGCRCHRM1TBXA2RADRA1ATDP1 | |
| SCHEMBL10940999 | 0.77 | HMGCR (0.48) | HMGCRCHRM1TBXA2RADRA1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107898775-A | IBC2 compounds are preparing the application in preventing and treating bladder cancer drug | 李翀 | 2018-04-13 | — | — | CN | claimed |
| CN-107898775-A | IBC2 compounds are preparing the application in preventing and treating bladder cancer drug | 李翀 | 2018-04-13 | — | — | CN | disclosed |
| US-9283199-B2 | Halogenated aliphatic carboxylic acids, oligomers and/or polymers thereof and their use in devitalizing external and internal neoplasms | CIMAS LIMITED (CY) | 2016-03-15 | — | — | US | disclosed |
| US-20160067198-A1 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | CIMAS LIMITED (CY) | 2016-03-10 | — | — | US | disclosed |
| CN-102695503-A | Halogenated aliphatic carboxylic acids, oligomers and/or polymers thereof and their use for inactivating external and internal neoplasias | MARDI MEDICINES LTD | 2012-09-26 | — | — | CN | disclosed |
| EP-2440198-A2 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | Mardi Medicines Ltd. (IL) | 2012-04-18 | — | — | EP | disclosed |
| US-20110052641-A1 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | MARDI MEDICINES LTD. (IL) | 2011-03-03 | — | — | US | disclosed |
| WO-2010143188-A2 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | MARDI MEDICINES LTD. (IL) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067198-A1 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | CCR10, PBK, CCR3 | HMGCR 3373/4885CHRM1 2072/4885TBXA2R 2987/4885 |
| US-20110052641-A1 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | CCR10, PBK, CCR3 | HMGCR 3373/4885CHRM1 2072/4885TBXA2R 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.